Physician profile
Christopher Young
NPI 1447981485
$2,720.27
in general payments reported to CMS, 2019-2025
35 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.98 · 2023: $40.86 · 2024: $435 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.48 | 2024-2025 | |
| Novo Nordisk INC | $231.97 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $228.72 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $214.44 | 2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $173.67 | 2024-2025 | Voquezna |
| Lundbeck LLC | $156.48 | 2025 | Rexulti, Vyepti |
| Vanda Pharmaceuticals INC. | $135.19 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $129.50 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $127.04 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.70 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $118.29 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $102.06 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $88.72 | 2024-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $78.18 | 2025 | Trintellix |
| Pfizer INC. | $67.24 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $62.92 | 2025 | Quillichew Er, Dyanavel Xr, Quillivant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.13 | 2025 | Xifaxan |
| Ardelyx, INC. | $35.38 | 2025 | Ibsrela |
| Ironshore Pharmaceuticals INC. | $32.12 | 2024 | |
| Merck Sharp & Dohme LLC | $31.70 | 2025 | Gardasil 9, Capvaxive, Enflonsia |
| Ani Pharmaceuticals, INC. | $31.30 | 2025 | Purified Cortrophin Gel |
| Phadia US INC. | $30.04 | 2024 | Immunocap |
| Exact Sciences Corporation | $27.28 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.98 | 2022 | |
| Corium, LLC | $20.66 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $20.06 | 2025 | Ajovy |
| Aimmune Therapeutics, INC. | $17.76 | 2024 | |
| Dexcom, INC. | $17.49 | 2025 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $16.46 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $16.26 | 2024 | Entre Plus, Flexitouch Plus |
| Kowa Pharmaceuticals America, INC. | $15.97 | 2025 | Zoryve |
| Seqirus USA INC | $15.91 | 2025 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.33 | 2025 | Jardiance |
| Recordati_rare_diseases_inc. | $15.18 | 2025 | Isturisa |
| Abbott Laboratories | $13.66 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.